Document is current

Article History

Received: 6 November 2024

Accepted: 21 January 2025

First Online: 4 February 2025

Declarations

:

: The study received approval from both the Ethics Committee of the Medical Faculty Mannheim, Heidelberg University (Title of the approved project: Investigation of the pathophysiology of arrhythmias using cardiomyocytes derived from human induced pluripotent stem cells (hiPSC) in various cardiovascular diseases, Approval number: 2018–565 N-MA, Date of approval: 19/06/2018) and the Ethics Committee of the University Medical Center Göttingen (Title of the approved project: Reprogramming somatic cells into induced pluripotent stem cells to establish a human biobank as a resource for the study of human diseases, Approval No. 10/9/15, Date of approval: February 2, 2016.). Human cardiac microvascular endothelial cells (HCMECs) were purchased from PromoCell (Cat.No: C-12285, PromoCell GmbH, Heidelberg, Germany). The tissues used by PromoCell for the isolation of human cell cultures were sourced from donors who have signed a declaration of consent. The donor acquisition process, documents and cell collection procedures implemented by PromoCell have been evaluated and approved by the ethical commission of the doctor’s medical association of Baden-Württemberg (# 219-04). The patients or their guardians /next of kin provided written informed consent for participation in the study and/or the use of samples. The study was conducted in compliance with the approved guidelines and in accordance with the Helsinki Declaration of 1975 (, accessed on 30 May 2022), revised in 2013.

: The authors declare that they have no conflicts of interest.